Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size redu

– Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size re

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment

See Stanley Druckenmiller's Q2 13F filing. Duquesne adds Microsoft and big banks, cuts Coupang,

Immunome's lead asset, varegacestat, shows promising efficacy in desmoid tumors, with phase 3 toplin

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults

DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technolog

– If approved, nirogacestat will be the first and only therapy with marketing authorization in the E

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,

SWTX wins CHMP backing for mirdametinib in NF1-PN. EU nod is expected in the third quarter of 2025.

– If approved, mirdametinib is expected to be the first and only therapy in the European Union with

SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.11 per share versus the Zacks C

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,

The average of price targets set by Wall Street analysts indicates a potential upside of 42.3% in Sp

NEW YORK , April 28, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"),

NEW YORK , April 28, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law

Merck & Company, Inc. (MRK) to acquire SpringWorks Therapeutics, Inc. (SWTX) for $47/share in ca

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating SpringWorks (Nasdaq: SWTX) for possible

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t

Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%

Shares of Titan Machinery Inc. (NASDAQ: TITN) moved lower during Thursday’s trading following weak q

Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the comp

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday

Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Frid

Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares rose 60.2% to $1.7136. Avadel Pharmaceut

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday.

Gainers Adicet Bio, Inc. (NASDAQ: ACET) rose 16% to $11.90 in pre-market trading after reporting

  On Friday, 1043 companies hit new 52-week lows.

  During Thursday, 849 stocks hit new 52-week lows.

    On Monday, 721 companies achieved new lows for the year.

    On Thursday, 236 companies hit new 52-week lows.

    On Tuesday, 596 companies set new 52-week highs.

    Monday morning saw 558 companies set new 52-week highs.

  Before 10 a.m. ET on Thursday, 166 companies hit new 52-week highs.

  During Tuesday's morning session, 342 companies made new 52-week highs.

  During Thursday's morning session, 316 companies made new 52-week highs.

  This morning 167 companies reached new 52-week highs.

  Before 10 a.m. ET on Wednesday, 322 companies hit new 52-week highs.

  Before 10 a.m. ET on Wednesday, 185 stocks hit new 52-week highs.

  This morning 180 companies set new 52-week highs.